Original Article
  

Sublingual Immunotherapy with Sal k1 Expressing Lactococcus lactis Down-regulates Th2 Immune Responses in Balb/c Mice

Abstract

Sublingual immunotherapy (SLIT) has been introduced as a noninvasive and safer approach for allergen-specific immunotherapies. In this study we investigated the efficacy of oral immunotherapy with recombinant Salsola kali 1 protein (Sal k 1) on Th1/Th2 balance in a mouse model of allergy. Female Balb/c mice were intraperitoneally sensitized with rSal k1, followed by a respiratory challenge with 1% (w/v) rSal k1. The sensitized mice were subjected to SLIT using rSal K1 expressing Lactobacillus lactis strain for three weeks. Each week the experimental group underwent SLIT protocol twice. Finally, serum levels of specific immunoglobulins including IgE, IgG1 and IgG2a, as well as secretion of different cytokines from splenocytes including IL-2, IL-4, IL-10, IFNγ and TGFβ into culture media were measured by ELISA. Following immunotherapy, the levels of specific IgE and IgG1 in mice sera as well as IL-4 level in supernatant of splenocytes were significantly lower than allergic controls. While serum IgG2a, IgG2a/IgG1 ratio as well as concentration of IL-2, IL-10, IFNγ, and TGFβ were higher in the SLIT group compared to the controls. The histopathological examination of intestinal tissues revealed no sign of inflammatory response following SLIT. This study revealed that Th2 immune responses are reduced in allergic mice after feeding them with allergen expressing probiotic bacteria as a SLIT approach. Since the safety of this procedure was previously approved, thus, it seems that a similar protocol using human based probiotics could be applied for Salsola kali sensitive patients.

  1. Wahn U. What drives the allergic march? Allergy 2000: 55(7):591-9.
  2. Aalberse Rc. Structural biology of allergens. J Allergy Clin Immunol 2000; 106(2):228-380.
  3. Assarehzadegan MA, Shakurnia A, Amini A. The most common aeroallergens in a tropical region in Southwestern Iran. World Allergy Organ J 2013; 6(1):7.
  4. Wahn U, Taba Ar, Kuna P, Halken S, Montagut A, Beaumo O de nt , et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123(1):160-6.
  5. Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81(5):401-5.
  6. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6(10):761-71.
  7. Bergmann KC, Demoly P, Worm M, Fokkens WJ, Carrillo T, Tabar AI, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014; 133(6):1608-14.
  8. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann F, Rufin P, et al. Safety of various dosage regimens during induction of sublingual immunotherapy. Int Arch Allergy Immunol 2002; 129(3):248-53.
  9. Shima K, Koya T, Tsukioka K, Sakagami T, Hasegawa T, Fukano, et al. Effects of sublingual immunotherapy in a murine asthma model sensitized by intranasal administration of house dust mite extracts. Allergol Int 2017; 66(1)89-96.
  10. Novak N, Haberstok J, Bieber T, Allam J-P. The immune privilege of the oral mucosa. Trends Mol Med 2008; 14(5):191-8.
  11. Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9(6):554-7.
  12. Salari F, Varasteh AR, Vahedi F, Hashemi M, Sankian M. Down-regulation of Th2 immune responses by sublingual administration of poly (lactic-co-glycolic) acid (PLGA)-encapsulated allergen in BALB/c mice. Int Immunopharmacol 2015; 29(2):672-8.
  13. Spertini F, Reymond C, Leimgruber A. Allergen-specific immunotherapy of allergy and asthma: current and future trends. Expert Rev Respir Med 2009; 3(1):37-51.
  14. Bahey-El-Din M, Gahan CG, Griffin BT. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 2010; 10(1):34-45.
  15. Bermudez-Humaran LG, Kharrat P, Chatel JM, Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines, Microb Cell Fact 2011; (10 Suppl 1):S4.
  16. Daniel C, Repa A, Wild C, Pollak A, Pot B, Breiteneder H, et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 2006; 61(7):812-9.
  17. Assarehzadegan MA, Sankian M, Jabbari F, Noorbakhsh R, Varasteh A. Allergy to Salsola Kali in a Salsola incanescens-rich area: role of extensive cross allergenicity. Allergol Int 2009; 58(2):261-6.
  18. Ferrer A, Larramendi CH, Huertas AJ, Pagan JA, Andreu C, Garcia-Abujeta JL, et al. Allergenic differences among pollens of three Salsola species. Int Arch Allergy Immunol 2010; 151(3):199-206.
  19. Carnes J, Fernandez-Caldas E, Marina A, Alonso C, Lahoz C, Colas C, et al. Immunochemical characterization of Russian thistle (Salsola kali) pollen extracts, Purification of the allergen Sal k 1. Allergy 2003; 58:1152-6.
  20. Groh N, Seutter von Loetzen C, Subbarayal B, Möbs C, Vogel L, et al. IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen. Clin Exp Allergy 2017; 47(5):693-703.
  21. Scadding G, Shamji M, Jacobson M, Lee D, Wilson D, Lima M, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen‐specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40(4):598-606.
  22. Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy 2006; 61:11-4.
  23. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2(6):446-53.
  24. Coffman RL, Seymour BWP, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, et al. The Role of Helper T Cell Products in Mouse B Cell Differentiation and Isotype Regulation. Immunol Rev 1988; 102:5-28.
  25. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61(2):151-65.
  26. Gabrielsson S, Söderlund A, Paulie S, Van Der Pouw Kraan TCTM, Troye-Blomberg M, Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 2006; 56(4):293-300.
  27. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013; 131:1288-96.
  28. Umetsu DT, Akbari O, DeKruyff RH, Shearer WT, Rosenwasser LJ, Bochner BS. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003; 112(3):480-7.
  29. Grindebacke H, Wing K, Andersson AC, Suri‐Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4+ CD25+ regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004; 34(9):1364-72.
  30. Sakaguchi S, Sakaguchi N, Asano M, Itoh M,Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3):1151-64.
  31. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95(1):38-44.
  32. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22(1):87-95.
  33. Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy 2007; 37(4):498-505.

Files
IssueVol 17, No 3 (2018) QRcode
SectionOriginal Article(s)
Keywords
Lactococcus lactis Salsola kali Sublingual immunotherapy
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ghasemi Z, Varasteh A-R, Moghadam M, Jalali S-A, Anissian A, Sankian M. Sublingual Immunotherapy with Sal k1 Expressing Lactococcus lactis Down-regulates Th2 Immune Responses in Balb/c Mice. Iran J Allergy Asthma Immunol. 2018;17(3):281-290.